Sanara MedTech Toekomstige groei

Future criteriumcontroles 1/6

De verwachting is dat Sanara MedTech de winst en omzet met respectievelijk 10% en 16.1% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 15.6% per jaar.

Belangrijke informatie

10.0%

Groei van de winst

15.6%

Groei van de winst per aandeel

Medical Equipment winstgroei	17.1%
Inkomstengroei	16.1%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	13 Nov 2024

Recente toekomstige groei-updates

US$44.00: That's What Analysts Think Sanara MedTech Inc. (NASDAQ:SMTI) Is Worth After Its Latest Results

Nov 15

Sanara MedTech Inc. (NASDAQ:SMTI) Analysts Are Pretty Bullish On The Stock After Recent Results

Mar 22

Recent updates

US$44.00: That's What Analysts Think Sanara MedTech Inc. (NASDAQ:SMTI) Is Worth After Its Latest Results

Nov 15

Sanara MedTech Inc. (NASDAQ:SMTI) Analysts Are Pretty Bullish On The Stock After Recent Results

Mar 22

Sanara MedTech: Differentiated Offering With Niche Wound Care Exposure

Sep 06

Sanara MedTech reports Q2 results

Aug 15

Here's Why We're Not At All Concerned With Sanara MedTech's (NASDAQ:SMTI) Cash Burn Situation

Dec 31

Sanara MedTech: Technology For Faster Healing Wounds

Dec 08

Sanara Medtech inks exclusive partnership with Pixalere Healthcare

Jun 04

Companies Like Sanara MedTech (NASDAQ:SMTI) Can Afford To Invest In Growth

May 18

Neil Cataldi From Blueprint Discusses Sanara MedTech

May 03

The Sanara MedTech (NASDAQ:SMTI) Share Price Has Soared 510%, Delighting Many Shareholders

Feb 19

Is Sanara MedTech Inc. (NASDAQ:SMTI) Popular Amongst Insiders?

Dec 28

Winst- en omzetgroeiprognoses

NasdaqCM:SMTI - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	112	-7	N/A	N/A	1
12/31/2025	99	-10	N/A	N/A	1
12/31/2024	83	-11	N/A	N/A	1
9/30/2024	78	-8	-2	-2	N/A
6/30/2024	72	-7	-3	-3	N/A
3/31/2024	68	-5	-3	-3	N/A
12/31/2023	65	-4	-4	-3	N/A
9/30/2023	63	-8	-3	-3	N/A
6/30/2023	60	-9	-4	-6	N/A
3/31/2023	54	-6	-6	-5	N/A
12/31/2022	46	-8	-6	-6	N/A
9/30/2022	38	-7	-8	-7	N/A
6/30/2022	30	-8	-9	-6	N/A
3/31/2022	27	-10	-6	-6	N/A
12/31/2021	24	-8	-6	-5	N/A
9/30/2021	22	-5	-5	-4	N/A
6/30/2021	20	-4	-3	-3	N/A
3/31/2021	17	-4	-4	-3	N/A
12/31/2020	16	-4	-6	-4	N/A
9/30/2020	14	-6	-6	-4	N/A
6/30/2020	13	-5	-6	-4	N/A
3/31/2020	13	-4	-6	-4	N/A
12/31/2019	12	-3	-4	-2	N/A
9/30/2019	11	-1	-2	-1	N/A
6/30/2019	10	0	-1	-1	N/A
3/31/2019	9	0	0	0	N/A
12/31/2018	9	0	0	1	N/A
9/30/2018	8	0	1	1	N/A
6/30/2018	7	0	N/A	0	N/A
3/31/2018	7	0	N/A	0	N/A
12/31/2017	6	0	N/A	0	N/A
9/30/2017	6	0	N/A	0	N/A
6/30/2017	6	0	N/A	1	N/A
3/31/2017	6	-1	N/A	0	N/A
12/31/2016	6	-1	N/A	0	N/A
9/30/2016	4	-1	N/A	0	N/A
6/30/2016	4	-2	N/A	-1	N/A
3/31/2016	3	-1	N/A	-1	N/A
12/31/2015	3	-2	N/A	-1	N/A
9/30/2015	3	-1	N/A	-1	N/A
6/30/2015	3	-2	N/A	-1	N/A
3/31/2015	3	-2	N/A	-1	N/A
12/31/2014	3	-3	N/A	-2	N/A
9/30/2014	2	-4	N/A	-2	N/A
6/30/2014	2	-5	N/A	-2	N/A
3/31/2014	2	-4	N/A	-2	N/A
12/31/2013	2	-4	N/A	-2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat SMTI de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat SMTI de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat SMTI de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van SMTI ( 16.1% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van SMTI ( 16.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van SMTI naar verwachting over 3 jaar hoog zal zijn

Sanara MedTech Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus estimates of losses per share improve by 30%

US$44.00: That's What Analysts Think Sanara MedTech Inc. (NASDAQ:SMTI) Is Worth After Its Latest Results

Consensus EPS estimates fall by 157%, revenue upgraded

Price target decreased by 18% to US$49.00

Sanara MedTech Inc. (NASDAQ:SMTI) Analysts Are Pretty Bullish On The Stock After Recent Results

Forecast breakeven date pushed back to 2024

Recent updates

Consensus estimates of losses per share improve by 30%

US$44.00: That's What Analysts Think Sanara MedTech Inc. (NASDAQ:SMTI) Is Worth After Its Latest Results

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sanara MedTech Inc. to Report Q3, 2024 Results on Nov 12, 2024

Sanara MedTech Inc. Announces Changes to Its Board of Directors

Sanara MedTech Inc. (NASDAQ:SMTI) Looks Just Right With A 28% Price Jump

Consensus EPS estimates fall by 157%, revenue upgraded

Here's Why Sanara MedTech (NASDAQ:SMTI) Can Afford Some Debt

New major risk - Revenue and earnings growth

Sanara MedTech Inc. to Report Q2, 2024 Results on Aug 12, 2024

Sanara MedTech Inc.'s (NASDAQ:SMTI) Shares Not Telling The Full Story

Sanara MedTech Inc. Announces CEO Changes

First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.14 loss in 1Q 2023)

Sanara MedTech Inc. to Report Q1, 2024 Results on May 13, 2024

Sanara MedTech Inc., Annual General Meeting, Jun 12, 2024

Sanara MedTech Inc. Announces Executive Changes, Effective April 15, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Sanara MedTech Inc. to Report Q4, 2023 Results on Mar 25, 2024

Price target decreased by 18% to US$49.00

Is Sanara MedTech (NASDAQ:SMTI) Using Too Much Debt?

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.18 loss in 3Q 2022)

Sanara MedTech Inc. to Report Q3, 2023 Results on Nov 13, 2023

Sanara MedTech Inc. Announces BIASURGE Advanced Surgical Solution Updates

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Sanara MedTech Inc. (NasdaqCM:SMTI) acquired Certain Assets Related to its Collagen Products Business from Applied Nutritionals, LLC, The Hymed Group Corporation, and Dr. George Petito for 25.3 million.

High number of new directors

Sanara MedTech Inc. Elects Robert Desutter as Board of Director

Investors Still Waiting For A Pull Back In Sanara MedTech Inc. (NASDAQ:SMTI)

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sanara MedTech Inc. to Report Q1, 2023 Results on May 15, 2023

Sanara MedTech Inc. (NASDAQ:SMTI) Analysts Are Pretty Bullish On The Stock After Recent Results

Forecast breakeven date pushed back to 2024

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Sanara MedTech Inc. Announces Resignation of Shawn M. Bowman as President, Strategic Partnerships

Forecast to breakeven in 2023

Sanara MedTech Inc. to Report Q3, 2022 Results on Nov 14, 2022

President of Strategic Partnerships notifies of intention to sell stock

Sanara MedTech: Differentiated Offering With Niche Wound Care Exposure

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sanara MedTech reports Q2 results

Sanara MedTech Inc. to Report Q2, 2022 Results on Aug 15, 2022

Sanara MedTech Inc acquired Scendia Biologics, LLC from Ryan Phillips for $7.4 million.

No longer forecast to breakeven

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Sanara MedTech Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Sanara MedTech Inc., Annual General Meeting, Jun 10, 2022

Sanara MedTech Inc., Annual General Meeting, Jun 10, 2022

Here's Why We're Not At All Concerned With Sanara MedTech's (NASDAQ:SMTI) Cash Burn Situation

Sanara MedTech: Technology For Faster Healing Wounds

Third quarter 2021 earnings released: US$0.27 loss per share (vs US$0.18 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.18 loss in 2Q 2020)

Sanara Medtech inks exclusive partnership with Pixalere Healthcare

Companies Like Sanara MedTech (NASDAQ:SMTI) Can Afford To Invest In Growth

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.39 loss in 1Q 2020)

Neil Cataldi From Blueprint Discusses Sanara MedTech

Full year 2020 earnings released: US$0.76 loss per share (vs US$1.32 loss in FY 2019)

The Sanara MedTech (NASDAQ:SMTI) Share Price Has Soared 510%, Delighting Many Shareholders

New 90-day low: US$30.00

Is Sanara MedTech Inc. (NASDAQ:SMTI) Popular Amongst Insiders?

Sanara MedTech Inc. Appoints Sara Ortwein as Director

New 90-day high: US$41.35

Third quarter 2020 earnings released: US$0.18 loss per share

New 90-day high: US$34.24

Sanara MedTech Inc Appoints Bob Desutter to the Company's Board of Directors

Winst- en omzetgroeiprognoses